antithrombotics

Abciximab - Apixaban - Bivalirudin - Coumadin - Dabigatran - Deltaparin - Dicoumarol - Edoxaban - Eptifibatide - Fondaparinux - Fraxiparin - Heparin - Hirudin - Idraparinux - LMWH - Reviparin - Rivaroxaban - Tirofiban - UFH - Wafarin - Warfarin - Ximelagatran      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome  

apixaban  
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
argatroban  
ARGAMI-2, 1998       Argatrobanheparin -
aspirin  
ATACS-pilot, 1990   aspirincontrolnegative
VA-pilot   aspirinplacebonegative
VA-main, 1983   aspirinplaceboLow risk of bias suggesting
RISC, 1990   aspirinplaceboLow risk of bias suggesting
ALDUSA-pilot   aspirinplacebonegative
Théroux, 1988   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative
atopaxar  
LANCELOT ACS     atopaxarplaceboExploratory -
J-LANCELOT, 2010   atopaxarplaceboExploratory -
bivalirudin  
ACUITY (biva alone vs hep+aGP2b3a), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsLow risk of bias suggesting-23%19%
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006    NCTbivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsLow risk of bias negative-6%13%
PROTECT-TIMI 30, 2006      NCTbivalirudineptifibatide + heparinExploratory -
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
BAT (Bittl), 1995     bivalirudinheparinLow risk of bias suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007         bivalirudinheparin + GP2b3a inhibitorssuggesting-48%19%
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007     bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsnegative11%28%
clopidogrel  
CURE (PCI sub study), 2001     clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting 38%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative 24%-4%
coumadin  
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dalteparin  
FRISC (long term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias suggesting-15%
FRIC prolonged treatment phase (LWMH vs PBO), 1997     dalteparinplacebo (on top of aspirin)Low risk of bias negative61%
FRISC (short term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias -
FRIC (acute phase LMWH vs UFH), 1997     dalteparinUFH (on top of aspirin)Exploratory negative257%
dipyridamol  
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative
Efegatran  
Klootwijk, 1999     EfegatranheparinExploratory -
enoxaparin  
RESCUE    NCTenoxaparinunfractionated heparin -
EVET, 2005     enoxaparintinzaparinsuggesting-50%
ESSENCE, 1997     enoxaparinUFH (on top of aspirin)Low risk of bias suggesting -7%-3%
TIMI 11 B (short term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias suggesting 52%-17%
SYNERGY, 2005          NCTenoxaparinUFH (on top of aspirin)negative 19%4%
INTERACT, 2006       enoxaparinUFH (on top of aspirin)suggesting -60%-42%
TIMI 11 B (long term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias negative 90%-4%
fondaparinux  
PENTUA, 2004     fondaparinuxenoxaparin -
OASIS 5, 2006      NCTfondaparinuxenoxaparinLow risk of bias -
hirudin  
HIT-4, 1999     HirudinheparinLow risk of bias -
TIMI 9B, 1996     HirudinheparinRisk of bias -
GUSTO IIB, 1996     HirudinheparinRisk of bias -
OASIS pilot, 1997     HirudinheparinExploratory -
HELVETICA (Serruys), 1995     HirudinheparinLow risk of bias -
OASIS 2, 1999     HirudinheparinLow risk of bias -
OASIS, 1997   HirudinheparinRisk of bias -
inogatran  
TRIM, 1997     InogatranheparinLow risk of bias -
nadroparin  
FRAXIS (6days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative6%
FRAXIS (14 days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative26%
otamixaban  
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
prasugrel  
TRILOGY ACS (overall population), 2012        NCTprasugrelclopidogrelLow risk of bias negative21%-6%
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting 31%-5%
rivaroxaban  
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
sulfinpyrazone  
Canadian (sulfinpyrazone alone), 1985   sulfinpyrazoneplaceboLow risk of bias -
ticagrelor  
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting3%-22%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative-2%37%
ticlopidine  
STAI, 1990   ticlopidinecontrolsuggesting
Florida UA   ticlopidineplacebonegative
trapidil  
Modena   trapidilplacebosuggesting
triflusal  
TIM, 2000     triflusalaspirinLow risk of bias -
Plaza, 1993   triflusalplaceboLow risk of bias suggesting
UFH  
Holdright, 1994   UFHcontrol (on top of aspirin)negative-15%
RISC (heparin+aspirin vs ASP), 1990   UFHcontrol (on top of aspirin)negative
Theroux (heparin+ASP vs ASP), 1988   UFHcontrol (on top of aspirin)Low risk of bias suggesting
ATACS (Cohen), 1994   UFH, warfarincontrol (on top of aspirin)negative606%4%
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990     UFH, warfarincontrol (on top of aspirin)negative
Theroux (heparin vs PBO), 1988   UFHplaceboLow risk of bias suggesting0%-100%
RISC (heparin vs PBO), 1990   UFHplacebonegative
Theroux (heparin+aspirin vs PBO), 1988   UFH + aspirinplaceboLow risk of bias suggesting-100%
RISC (ASP+ heparin vs PBO), 1990   UFH + aspirinplacebosuggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995     UFHplacebo (on top of aspirin)Low risk of bias negative421%
Cohen (ATACS pilot) (heparin vs asp), 1990     UFH, warfarinaspirinnegative
vorapaxar  
TRACER, 2011      NCTvorapaxarplacebo (on top standard therapy) Low risk of bias -
warfarin  
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
ATACS, 1994   warfarincontrol (on top of aspirin)negative∞%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative∞%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative
ximelagatran  
ESTEEM, 2003   ximelagatranplaceboExploratory -

acute myocardial infarction  

argatroban  
ARGAMI-2, 1998       Argatrobanheparin -
bivalirudin  
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
coumadin  
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative 126%-42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting 285%-10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting3%-72%
dalteparin  
FRAMI, 1997     Dalteparinplacebo -
BIOMACS II, 1999     DalteparinplaceboLow risk of bias -
ASSENT Plus, 2003     DalteparinUFHnegative
enoxaparin  
AMI-SK, 2002     EnoxaparinplaceboLow risk of bias -
ASSENT 3, 2001     EnoxaparinUFHsuggesting
HART II, 2001     EnoxaparinUFHnegative
Baird, 2002     EnoxaparinUFHnegative
ENTIRE-TIMI 2, 2002     EnoxaparinUFHsuggesting
ASSENT 3 Plus, 2003     EnoxaparinUFHnegative
fondaparinux  
MICHELANGELO OASIS-6, 2006      NCTfondaparinuxplaceboLow risk of bias suggesting-17%
hirudin  
HIT-4, 1999     HirudinheparinLow risk of bias -
TIMI 9B, 1996     HirudinheparinRisk of bias -
reviparin  
CREATE, 2005     ReviparinplaceboLow risk of bias -
UFH  
ISIS-2 Pilot, 1987     UFHno heparinnegative
DUCCS, 1994   UFHno heparinnegative
ECSG, 1992     UFHplaceboLow risk of bias negative
OSIRIS, 1992   UFHplaceboLow risk of bias negative
warfarin  
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting3%∞%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative 150%-67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting9%-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting 123%-5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 45%3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting 232%-2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting∞%-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 309%3%

atrial fibrillation  

apixaban  
AVERROES, 2011        NCTapixabanaspirinineligible for VKALow risk of bias suggesting 14%-21%
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-30%-11%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
aspirin  
LASAF(aspirin vs no treatment), 1999     aspirincontrol -
AFASAK (aspirin vs placebo), 1989   aspirinplaceboLow risk of bias negative∞%
SPAF (aspirin,warfarin ineligible arm), 1991   aspirinplaceboineligible for VKALow risk of bias negative
SPAF (aspirin , warfarin eligible arm), 1991   aspirinplaceboLow risk of bias suggesting
EAFT, 1993   aspirinplaceboLow risk of bias negative
FFAACS , 2001     aspirinplacebo (on top fluidione)Low risk of bias negative
PATAF (vs coumadin low dose), 1999     aspirincoumadin low doseRisk of bias negative
PATAF (vs coumadin standard dose), 1999     aspirincoumadin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin low dose), 1998     aspirinwarfarin low doseRisk of bias negative65%131%
SPAF II (aspirin vs warfarin standard dose, age<75), 1994   aspirinwarfarin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin standard dose), 1998     aspirinwarfarin standard doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994   aspirinwarfarin standard doseRisk of bias negative
AFASAK (aspirin vs warfarin standard dose), 1989   aspirinwarfarin standard doseRisk of bias negative
clopidogrel  
ACTIVE W, 2006    NCTaspirin + clopidogrelanticoagulantRisk of bias suggesting 10%2%
ACTIVE A, 2009      NCTaspirin + clopidogrelaspirinLow risk of bias suggesting 57%-2%
coumadin  
PATAF (coumadin low dose vs coumadin standard dose), 1999     coumadin low dosecoumadin standard doseRisk of bias negative
dabigatran  
RE-LY 110mg (2nd prevention subgroup) , 2010   dabigatran 100mgwarfarinExploratory suggesting
RE-LY 150mg (2nd prevention subgroup)   dabigatran 150mgwarfarinExploratory suggesting
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-20%-9%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -7%-12%
edoxaban  
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -20%-8%
idraparinux  
AMADEUS, 2008      NCTidraparinuxwarfarin standard doseRisk of bias negative 167%12%
rivaroxaban  
ROCKET (2nd prevention subgroup) , 2011   rivaroxabanwarfarinLow risk of bias negative
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting 4%-8%
triflusal  
NASPEAF (triflusal vs coumadin standard dose)), 2004     triflusalcoumadin standard doseRisk of bias negative
warfarin  
BAATAF (warfarin vs no treatment), 1990    NCTwarfarin low dosecontrolRisk of bias suggesting 96%-58%
SAFT(warfarin low dose + aspirin vs no treatment), 2003     warfarin low dose + aspirincontrolRisk of bias negative -14%
AFASAK (warfarin standard dose vs control), 1989   warfarin standard dosecontrolRisk of bias suggesting∞%
SPAF (warfarin standard dose), 1991   warfarin standard dosecontrolRisk of bias suggesting0%-25%
SPINAF (warfarin vs placebo), 1992   warfarin low doseplaceboLow risk of bias negative
CAFA, 1991   warfarin standard doseplaceboLow risk of bias negative411%
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998     warfarin + aspirinwarfarin standard doseRisk of bias negative
SPAF III, 1996   warfarin + aspirinwarfarin standard doseRisk of bias remark
AFASAK II (warfarin low dose vs warfarin standard dose), 1998     warfarin low dosewarfarin standard doseRisk of bias negative
MWNAF, 1998     warfarin low dosewarfarin standard doseRisk of bias negative
ximelagatran  
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting-29%-1%
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting -25%-6%

heart failure  

aspirin  
WASH (aspirin), 2004     aspirinno treatmentnegative ∞%40%
Barzizza (ASA), 1993   aspirinplaceboExploratory -
enoxaparin  
THE-PRINCE (Kleber), 2003     enoxaparinUFH -
rivaroxaban  
COMMANDER HF, 2018      NCTrivaroxabanplacebonegative-2%
warfarin  
WASH (warfarin), 2004     warfarinno treatmentnegative∞%17%
HELAS (warfarin vs placebo), 2006   warfarinplaceboLow risk of bias -
Barzizza (warfarin), 1993   warfarinplacebo -
HELAS (warfarin vs aspirin), 2006   warfarinaspirinLow risk of bias -
WATCH (warfarin vs aspirin), 2009      NCTwarfarinaspirinsuggesting43%-5%

percutaneous coronary intervention  

abciximab  
RAPPORT, 1998     Abciximabplacebo -
ADMIRAL, 2001     Abciximabplacebo -
CADILLAC, 2002     Abciximabplacebo -
EPIC (with infusion), 1994     Abciximabplacebo -
EPILOG, 1997     Abciximabplacebo -
EPISTENT, 1998         Abciximabplacebo -
CAPTURE, 1997     Abciximabplacebo -
ERASER, 1999     Abciximabplacebo -
Petronio, 2002     Abciximabplacebo -
Simoons, 1994   Abciximabplacebo -
Kini, 2001     Abciximabplacebo -
Tamburino, 2002   Abciximabplacebo -
ISAR-2, 2000     Abciximabplacebo -
aspirin  
Taylor (Perth), 1991     aspirinplaceboLow risk of bias negative
M-HEART II (aspirin), 1995     aspirinplaceboLow risk of bias negative
bivalirudin  
REPLACE-2, 2003         bivalirudinheparin + GP2b3a inhibitorsLow risk of bias -
HORIZONS-AMI (Stone), 2008        NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias suggesting-39%-34%
ACUITY (Stone) (bivalirudin alone), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias -
Kleiman, 2002     bivalirudin + eptifibatideheparin + GP2b3a inhibitorsExploratory -
ISAR-REACT 3, 2008    NCTbivalirudinUFHLow risk of bias -
REPLACE-1, 2004     bivalirudinUFHExploratory negative-100%
BAT (Bittl), 1995             bivalirudinUFHLow risk of bias suggesting-61%123%
ARMYDA BIVALVE   bivalirudinUFH -
NAPLES (Tavano), 2009     bivalirudinUFH plus tirofibanRisk of bias suggesting-75%
cangrelor  
CHAMPION PHOENIX, 2013        NCTcangrelorclopidogrelLow risk of bias suggesting50%0%
CHAMPION-PCI, 2009      NCTcangrelor up frontclopidogrel up frontLow risk of bias negative59%
CHAMPION-PLATFORM, 2009    NCTcangrelor up frontdelayed clopidogrelLow risk of bias negative
cilostazol  
Kunishima, 1997     cilostazolaspirinnegative
Sekiya, 1998     cilostazol + aspirinaspirinnegative
Kozuma, 2001     cilostazol + aspirinticlopidine + aspirinnegative
Ochiai, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Park, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Yoon, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Kamishirado, 2002     cilostazol + aspirinticlopidine + aspirinnegative
clopidogrel  
GRAVITAS, 2011      NCThigh-dose clopidogrelnormal-dose clopidogrelRisk of bias negative-30%
Müller, 2000     clopidogrel + aspirinticlopidine + aspirinnegative
CLASSICS, 2000     clopidogrel + aspirinticlopidine + aspirinnegative
TOPPS, 2001     clopidogrel + aspirinticlopidine + aspirinnegative
Piamsomboon, 2001   clopidogrel + aspirinticlopidine + aspirinnegative
dalteparin  
Natarajan (without antiGp2b3a), 2003   dalteparinUFH -
Natarajan (+ antiGp2b3a), 2003   dalteparinUFH + anti Gp2b3a -
dipyridamol  
Schwartz (Toronto), 1988   aspirin + dipyridamolplaceboLow risk of bias suggesting
White (aspirin+dipiridamol), 1991   aspirin + dipyridamolplacebonegative
Nye (Dunedin), 1990   aspirin + dipyridamolplacebonegative
Mayo-PTCA, 1989   aspirin + dipyridamolplacebonegative
elinogrel  
INNOVATE PCI          NCTelinogrelclopidogrel -
enoxaparin  
STEEPLE, 2006      NCTenoxaparinUFHRisk of bias -
Rabah, 1999     enoxaparinUFHExploratory negative
CRUISE, 2003     enoxaparinUFHExploratory negative
Galeote, 2001   enoxaparinUFHnegative
Dudek, 2000   enoxaparinUFHnegative
Dudek b (enox alone), 2000   enoxaparinUFH -
Drozd, 2001   enoxaparinUFHnegative
ATOLL, 2010   enoxaparinUFHRisk of bias -
Dubek b (+abciximal), 2001   enoxaparin+abciximabUFH -
eptifibatide  
IMPACT (4h), 1995     Eptifibatideplacebo -
IMPACT-II (0.5µg), 1997     Eptifibatideplacebo -
ESPRIT, 2000     Eptifibatideplacebo -
Harrington, 1995     Eptifibatideplacebo -
prasugrel  
TRITOM TIMI 38 (PCI subgroup), 2009     prasugrelclopidogrel -
JUMBO-TIMI 26, 2005   prasugrelclopidogrelLow risk of bias negative
reviparin  
REDUCE, 1996     reviparinUFHLow risk of bias suggesting
sulotroban  
M-HEART II (sulotroban), 1995   sulotrobanplaceboLow risk of bias -
ticlopidine  
TACT, 1990   ticlopidineplacebonegative
White (ticlopidine), 1991   ticlopidineplacebo -
STARS (vs aspirin), 1998     ticlopidine + aspirinaspirinsuggesting
Hall, 1996     ticlopidine + aspirinaspirinnegative
FANTASTIC, 1998     ticlopidine + aspirincoumadin + aspirinnegative
ISAR, 1996     ticlopidine + aspirincoumadin + aspirinsuggesting
Foussas, 2000   ticlopidine + aspirincoumadin + aspirinsuggesting
MATTIS, 1998     ticlopidine + aspirincoumadin + aspirinnegative
STARS (vs coumadin+asp), 1998     ticlopidine + aspirincoumadin + aspirinsuggesting
tirofiban  
RESTORE, 1997       Tirofibanplacebo -
Kereiakis, 1996     Tirofibanplacebo -

peripheral vascular diseases  

acenocoumarol  
APIC, 1989   acenocoumarolplacebo -
aspirin  
Lassila R, 1991   aspirincontrôle -
CLIPS, 2007     aspirinplaceboLow risk of bias suggesting71%
BOA, 2000   aspirin -
ticlopidine  
Becquemin, 1997   ticlopidinecontrôle -
UFH  
Antonicelli, 1999   HNFplacebo -
Tesi, 1989   HNFplacebo -
warfarin  
Johnson, 2002   warfarincontrôle -
Sarac, 1998   warfarincontrôle -

post acute coronary syndromes  

dabigatran  
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

post myocardial infarction  

dabigatran  
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

pulmonary embolism  

apixaban  
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting-51%
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting-75%
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-69%-21%
Certoparin  
Certoparin-Study Group sub group, 1998   Certoparinunfractionated heparinExploratory negative
dalteparin  
Kuijer, 1995   Dalteparinunfractionated heparinnegative
Meyer, 1995   Dalteparinunfractionated heparinnegative
enoxaparin  
PREPIC, 1998     Enoxaparinunfractionated heparinRisk of bias negative
Merli sub group, 2001     Enoxaparinunfractionated heparinExploratory negative
fondaparinux  
MATISSE PE, 2003   fondaparinuxheparinRisk of bias negative-15%19%
idraparinux  
VanGogh PE, 2007    NCTidraparinux (without heparin)heparin/VKARisk of bias negative -49%79%
nadroparin  
European multicentre study, 1991   Nadroparinunfractionated heparinRisk of bias negative
Prandoni sub-group, 1992       Nadroparinunfractionated heparinExploratory negative
Thery, 1992   Nadroparinunfractionated heparinExploratory negative
reviparin  
COLOMBUS sub group, 1997     Reviparinunfractionated heparinExploratory negative
rivaroxaban  
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
tinzaparin  
ACTSG (Hull) sub-group, 1992     Tinzaparinunfractionated heparinLow risk of bias negative
THESEE, 1997     Tinzaparinunfractionated heparinRisk of bias negative
Campbell, 1998   Tinzaparinunfractionated heparinnegative

stable angina  

aspirin  
SAPAT, 1992   aspirinplaceboLow risk of bias suggesting
clopidogrel  
ASCET    NCTclopidogrelaspirinRisk of bias negative
dipyridamol  
Atlanta (Sbar), 1967   dipyridamolcontrolLow risk of bias negative
Becker, 1967   dipyridamolcontrolLow risk of bias negative
Wirecki, 1967   dipyridamolcontrolLow risk of bias negative
Igloe, 1970   dipyridamolplaceboLow risk of bias -
Zion, 1961   dipyridamolplaceboLow risk of bias -
Kinsella, 1962   dipyridamolplaceboLow risk of bias -
Leiberman, 1964   dipyridamolplaceboLow risk of bias -
Dewar, 1961   dipyridamolplaceboLow risk of bias -
Neumann, 1964   dipyridamolplaceboLow risk of bias -
Foulds, 1960   dipyridamolplaceboLow risk of bias -
ticlopidine  
Berglund, 1985   ticlopidineplaceboLow risk of bias negative

stent  

cilostazol  
Kunishima, 1997     cilostazolaspirinnegative
Sekiya, 1998     cilostazol + aspirinaspirinnegative
Kozuma, 2001     cilostazol + aspirinticlopidine + aspirinnegative
Ochiai, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Park, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Yoon, 1999     cilostazol + aspirinticlopidine + aspirinnegative
Kamishirado, 2002     cilostazol + aspirinticlopidine + aspirinnegative
clopidogrel  
REAL-LATE, ZEST-LATE, 2010      NCTclopidogrel+aspirinaspirinnegative197%52%
GRAVITAS, 2011      NCThigh-dose clopidogrelnormal-dose clopidogrelRisk of bias negative-30%
Müller, 2000     clopidogrel + aspirinticlopidine + aspirinnegative
CLASSICS, 2000     clopidogrel + aspirinticlopidine + aspirinnegative
TOPPS, 2001     clopidogrel + aspirinticlopidine + aspirinnegative
Piamsomboon, 2001   clopidogrel + aspirinticlopidine + aspirinnegative
ticlopidine  
STARS (vs aspirin), 1998     ticlopidine + aspirinaspirinsuggesting
Hall, 1996     ticlopidine + aspirinaspirinnegative
FANTASTIC, 1998     ticlopidine + aspirincoumadin + aspirinnegative
ISAR, 1996     ticlopidine + aspirincoumadin + aspirinsuggesting
Foussas, 2000   ticlopidine + aspirincoumadin + aspirinsuggesting
MATTIS, 1998     ticlopidine + aspirincoumadin + aspirinnegative
STARS (vs coumadin+asp), 1998     ticlopidine + aspirincoumadin + aspirinsuggesting

superficial thrombophlebitis  

candesartan  
Andreozzi (200 vs 100), 1996   desmin 200desmin 100 -
Andreozzi (desmin SC vs 100), 1996   desmin SCdesmin 100 -
coumadin  
Belcaro (coumadin vs low dose hep), 1999   coumadinlow dose heparin -
defibrotide  
Belcaro, 1990   defibrotidelow dose heparin -
Diclofenac  
Nocker (diclofenac), 1991   Diclofenacplacebo -
enoxaparin  
Stenox (enoxaparin 40mg), 2003     enoxaparinplacebo -
STENOX (enoxaparin 1.5mg/hg), 2003   enoxaparinplacebo -
fondaparinux  
CALISTO, 2010    NCTfondaparinuxplaceboLow risk of bias suggesting
heparin  
Belcaro (hep vs defibrotide), 1990   heparin -
Gorski, 2005     heparin spraygelclexane -
Katzenschlager, 2003   liposomal heparin-spraygelenoxaparin -
Marchiori, 2002     heparinlow dose UFH -
Belcaro (hep vs no hep), 1989   heparinno treatment -
nadroparin  
Vesalio, 2005     nadroparin fixed-dosenadroparin weight-adjusted -
Titon (nadroparin 0.6ml vs naproxen), 1994   nadroparinnaproxene -
Titon (nadroparin 61.5 IU anti-Xa/kg vs naproxen), 1994   nadroparinnaproxene -
Nimesulide  
Ferrari, 1992   Nimesulidediclofenac -
UFH  
Belcaro (prophylactic UFH vs no), 1999   Prophylactic UFHno treatment -

thrombosis prevention  

acenocoumarol  
Hamulyak, 1994   AcenocoumarolNadroparinnegative60%
Samama, 2001     AcenocoumarolReviparinnegative 289%∞%
van Geloven, 1977   Acenocoumarolunfractionated heparinLow risk of bias -
apixaban  
ADOPT, 2011      NCTapixabanenoxaparinmedical patientsLow risk of bias suggesting153%
ADVANCE 3, 2010    NCTapixabanenoxaparinhip surgeryLow risk of bias suggesting22%199%
ADVANCE 2, 2010      NCTapixabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting-35%∞%
APROPOS 2.5mg, 2007    NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias negative∞%
ardeparin  
Levine, 1996   ardeparinplaceboknee surgeryLow risk of bias suggesting
Heit, 2000     out of hospital Ardeparinstandard prophylaxisnegative-35%-3%
Godwin, 1993   ardeparinunfractionated heparinabdominal surgery -
aspirin  
Clagett, 1975   aspirincontrolRisk of bias -
Zekert VI, 1982   aspirincontrolRisk of bias -
Pasteyer, 1977   Aspirinno treatmentExploratory negative
Rocha, 1986   Aspirinno treatmentExploratory suggesting
PEP hip-fracture, 2000     aspirinplaceboLow risk of bias suggesting 25%
Stockholm-I, 1975   AspirinplaceboExploratory negative
Harris-I, 1977   AspirinplaceboLow risk of bias suggesting
McKenna-I, 1980   AspirinplaceboExploratory suggesting
Sautter, 1983   AspirinplaceboExploratory suggesting
McBride, 1983   AspirinplaceboExploratory negative
Zekert-I , 1974   AspirinplaceboExploratory suggesting
Powers , 1976   AspirinplaceboExploratory suggesting
Erfurt-B , 1979   AspirinplaceboExploratory negative
MRC, 1972   aspirinplaceboLow risk of bias negative
Loew DVT, 1974   aspirinplaceboLow risk of bias -
Erfurt-A, 1979   aspirinplaceboLow risk of bias -
Zekert V, 1980   aspirinplaceboLow risk of bias -
Vinazzer I, 1980   aspirinplaceboLow risk of bias -
Vinazzer II, 1977   aspirinplaceboLow risk of bias -
PEP elective arthroplasty, 2000   aspirinplaceboLow risk of bias -
betrixaban  
APEX, 2016    NCTbetrixabanenoxaparinmedical patientsLow risk of bias suggesting19%
candesartan  
Ericksson, 1997     desirudinenoxaparinLow risk of bias -
REVASC, 1997     desirudinUFH -
Eriksson, 1996   desirudinUFHLow risk of bias -
Certoparin  
Kock, 1995   certoparincontrolRisk of bias negative
CERTIFY, 2010   certoparinUFHmedical patients -
Schmitz-Huebner, 1984   certoparinunfractionated heparinabdominal surgerynegative∞%
Sasahara, 1986   certoparinunfractionated heparinabdominal surgerysuggesting-61%
Voigt, 1986   certoparinunfractionated heparinabdominal surgerynegative183%-37%
Welzel, 1988   certoparinunfractionated heparinabdominal surgerysuggesting
Kakkar, 1989   certoparinunfractionated heparinabdominal surgerynegative∞%
Adolf, 1989   certoparinunfractionated heparinabdominal surgerynegative
Heilmann, 1989   certoparinunfractionated heparingynaecological surgerynegative-33%
Baumgartner, 1989   certoparinunfractionated heparinabdominal surgerynegative-48%
Hoffmann and Largiade, 1990   certoparinunfractionated heparinabdominal surgerynegative-3%
Koppenhagen, 1990   certoparinunfractionated heparinabdominal surgery -
Schielke, 1991   certoparinunfractionated heparinabdominal surgery -
Koppenhagen, 1992   certoparinunfractionated heparinabdominal surgery -
Hoffmann and Largiader, 1992   certoparinunfractionated heparinabdominal surgery -
Heilmann, 1997   certoparinunfractionated heparingynaecological surgery -
Haas, 1999   certoparinunfractionated heparingeneral surgery -
Haas , 1987   certoparine + DHEUnfractionated heparinhip surgerynegative
Lassen, 1988   certoparine + DHEUnfractionated heparinhip surgeryLow risk of bias suggesting
Lassen, 1989   certoparine + DHEUnfractionated heparinhip surgeryLow risk of bias negative109%
dabigatran  
RE-NOVATE (150mg), 2007      NCTdabigatran 150mgenoxaparinhip surgeryLow risk of bias negative -17%
RE-NOVATE (220mg), 2007      NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative29%∞%
RE-NOVATE 2    NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-MODEL (150mg), 2007     dabigatran 150mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative-1%-2%
RE-MODEL (220mg), 2007   dabigatran 220mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative14%1%
RE-MOBILIZE (150mg), 2008     dabigatran 150mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%∞%
RE-MOBILIZE (220mg), 2008     dabigatran 220mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%
dalteparin  
Jorgensen, 1989   dalteparinplacebohip surgeryLow risk of bias suggesting-100%
Torholm, 1991     dalteparinplacebohip surgeryLow risk of bias suggesting∞%
Leizorovicz, 2004     dalteparinplacebomedical patientsLow risk of bias suggesting∞%2%
Ockelford , 1989   dalteparinplacebosuggesting-7%-100%
Lapidus, 2007     dalteparinplaceboLow risk of bias negative
Lapidus, 2007     dalteparinplaceboLow risk of bias negative
D-KAf (Selby), 2007      NCTdalteparinplacebonegative
Eriksson , 1988   dalteparinDextranhip surgerysuggesting
Matzsch , 1988   dalteparinDextranhip surgerynegative
Matzsch , 1991   dalteparinDextranhip surgerysuggesting
Dahl, 1997   out of hospital Dalteparinstandard prophylaxissuggesting-2%
Lassen, 1998     out of hospital Dalteparinstandard prophylaxisnegative-100%
Hull, 2000     out of hospital Dalteparinstandard prophylaxissuggesting-100%
PROTECT, 2011    NCTdalteparinUFHmedical patientsLow risk of bias suggesting-2%-10%
Scala, 1990   dalteparinUFHRisk of bias negative-5%
Haas , 1985   dalteparinUnfractionated heparinhip surgerynegative
Binsack , 1986   dalteparinUnfractionated heparinhip surgerynegative
Barre , 1987   dalteparinUnfractionated heparinhip surgerynegative
Dechavanne , 1989   dalteparinUnfractionated heparinhip surgerynegative
Eriksson , 1989   dalteparinUnfractionated heparinhip surgerysuggesting-100%
Monreal , 1989   dalteparinUnfractionated heparinhip surgerynegative-36%
Bergqvist, 1986   dalteparinunfractionated heparinabdominal surgerynegative 236%
Onarheim, 1986   dalteparinunfractionated heparinabdominal surgerynegative8%
Koller, 1986   dalteparinunfractionated heparinabdominal surgerynegative 161%
Koller, 1986   dalteparinunfractionated heparinabdominal surgerynegative∞%
Fricker, 1988   dalteparinunfractionated heparinabdominal surgerynegative100%
Bergqvist, 1988   dalteparinunfractionated heparinabdominal surgerynegative -2%
Caen, 1988   dalteparinunfractionated heparinabdominal surgerynegative-100%-35%
Borstad, 1988   dalteparinunfractionated heparingynaecological surgerynegative5%
Briel, 1988   dalteparinunfractionated heparinnon orthopedic surgerynegative
Creperio, 1990   dalteparinunfractionated heparingeneral surgerynegative
Hartl, 1990   dalteparinunfractionated heparinabdominal surgerysuggesting-34%48%
Borstad, 1992   dalteparinunfractionated heparingynaecological surgery -
Kakkar, 1993   dalteparinunfractionated heparinabdominal surgery -
deltaparin  
Michot, 2002     deltaparincontrolRisk of bias suggesting
dipyridamol  
Chicago, 1982   aspirin + dipyridamolcontrolExploratory negative
Parodi I, 1973   dipyridamol + aspirincontrolExploratory suggesting
Parodi II, 1973   dipyridamol + aspirincontrolRisk of bias -
Zekert-III, 1977   dipyridamol + aspirincontrolRisk of bias -
Australian I, 1975   dipyridamol + aspirincontrolRisk of bias -
Australian II, 1976   dipyridamol + aspirincontrolRisk of bias -
Toulouse I, 1979   dipyridamol + aspirincontrolRisk of bias -
Harjola DVT, 1982   dipyridamol + aspirincontrolRisk of bias -
Weiss, 1977   dipyridamol + aspirincontrolExploratory -
Lyon-I, 1975   aspirin + dipyridamolno treatmentExploratory suggesting
Morris-B , 1977   aspirin + dipyridamolno treatmentExploratory negative
Morris-A , 1977   dipyridamolno treatmentExploratory negative
Hamburg, 1976   aspirin + dipyridamolplaceboExploratory negative
Encke-II , 1976   aspirin + dipyridamolplaceboExploratory negative
Frankfurt, 1981   aspirin + dipyridamolplaceboLow risk of bias negative
Encke IA, 1976   dipyridamol + aspirinplaceboLow risk of bias -
Encke IB, 1976   dipyridamol + aspirinplaceboLow risk of bias -
edoxaban  
STARS J-V    NCTedoxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
enoxaparin  
Canata, 2003   enoxaparincontrolExploratory negative
Warwick, 1995     enoxaparinno treatmenthip surgerynegative
Ho [43]   enoxaparinno treatmentnegative
Turpie, 1986   enoxaparinplacebohip surgeryLow risk of bias suggesting-100%
Leclerc, 1991   enoxaparinplaceboknee surgeryLow risk of bias suggesting
Samama, 1997     enoxaparinplacebohip surgeryLow risk of bias suggesting
Kalodiki, 1996   enoxaparinplacebohip surgeryLow risk of bias -
MEDENOX, 1999     Enoxaparinplacebomedical patientsLow risk of bias suggesting48%-26%
Lederle, 2006     Enoxaparinplacebomedical patientsLow risk of bias negative-60%
LIFENOX, 2011      NCTenoxaparinplacebomedical patientsLow risk of bias negative40%0%
LeGagneux , 1987   enoxaparinplacebonegative36%
Agnelli, 1998     enoxaparinplacebosuggesting
Melon, 1987   enoxaparinplacebonegative
DES Group , 1991   enoxaparinDextranhip surgerysuggesting∞%
Bergqvist, 1996     out of hospital Enoxaparinstandard prophylaxissuggesting
Planes, 1996     out of hospital Enoxaparinstandard prophylaxisnegative
Comp, 2001     out of hospital Enoxaparinstandard prophylaxissuggesting-100%-100%
Bergmann and Neuhart, 1996   enoxaparinUFHmedical patientsLow risk of bias negative-10%
Lechler, 1996   enoxaparinUFHmedical patientsLow risk of bias negative-36%
Kleber, 2003     enoxaparinUFHmedical patientsnegative-40%
Planes , 1988   enoxaparinUnfractionated heparinhip surgerysuggesting
Levine , 1991   enoxaparinUnfractionated heparinhip surgerynegative
Samama 1, 1988   enoxaparinunfractionated heparingeneral surgerynegative-1%∞%
Samama 2, 1988   enoxaparinunfractionated heparingeneral surgerynegative∞%∞%
Samama 3, 1988   enoxaparinunfractionated heparingeneral surgerynegative-8%∞%
Kaaja, 1992   enoxaparinunfractionated heparingynaecological surgery -
Gazzaniga (ISG), 1993   enoxaparinunfractionated heparingeneral surgery -
Nurmohamed, 1995   enoxaparinunfractionated heparingeneral surgery -
McLeod (Canadian), 1995   enoxaparinunfractionated heparinabdominal surgery -
Gonzalez, 1996   enoxaparinunfractionated heparinabdominal surgery -
ENOXACAN, 1997   enoxaparinunfractionated heparinabdominal surgery -
fondaparinux  
DRI4757   fondaparinuxplaceboknee surgeryLow risk of bias -
ARTEMIS (Cohen), 2006     fondaparinuxplacebomedical patientsLow risk of bias negative-3%-100%
APOLLO (Turpie), 2007     fondaparinuxplacebo (on top intermittent pneumatic comp.)abdominal surgeryLow risk of bias suggesting 924%-49%
PENTAMAKS (Bauer), 2001     fondaparinuxenoxaparinknee surgeryLow risk of bias suggesting 1000%-33%
PENTHIFRA (Eriksson), 2001     fondaparinuxenoxaparinhip surgeryLow risk of bias suggesting-4%-30%
PENTATHLON (Turpie), 2002     fondaparinuxenoxaparinhip surgeryLow risk of bias suggesting 82%200%
EPHESUS (Lassen), 2002     fondaparinuxenoxaparinhip surgeryLow risk of bias suggesting51%-100%
Turpie, 2001     fondaparinuxenoxaparinhip surgeryLow risk of bias -
L8541   fondaparinuxenoxaparinorthopaedic surgeryLow risk of bias negative-8%
L8635   fondaparinuxenoxaparinknee surgeryExploratory negative
BRiEF    NCTfondaparinuxenoxaparinmedical patients -
PEGASUS, 2005     fondaparinuxenoxaparinabdominal surgeryLow risk of bias negative39%-25%
fraxiparin  
Roth, 1995   nadroparincontrolnegative
Pezzuoli, 1989   nadroparinplacebosuggesting 151%-55%
Leyvraz, 1991   nadroparinUnfractionated heparinhip surgerynegative-49%
LMWH  
Harenberg, 1990     LMWHUFHmedical patientsLow risk of bias negative193%
Harenberg, 1996   LMWHUFHmedical patientsLow risk of bias negative 146%
nadroparin  
KANT (7 days), 2008   nadroparincontrolRisk of bias suggesting
Kujath, 1993   nadroparincontrolRisk of bias suggesting
KANT (14 days), 2008   nadroparin 14dcontrolRisk of bias suggesting
Yoo, 1997     nadroparinno treatmenthip surgerynegative
Marassi [41]   nadroparinno treatmentnegative
Sourmelis, 1995   nadroparinplacebohip surgeryLow risk of bias suggesting
Fraisse, 2000     Nadroparinplacebomedical patientsLow risk of bias negative109%5%
Mahe, 2005   Nadroparinplacebomedical patientsLow risk of bias negative-66%-2%
Bergmann, 1996   nadroparinplacebomedical patientsnegative-2%
Balas [40]   nadroparinplacebonegative
Nurmohamed, 1996   nadroparinplacebonegative
NPHDO, 1998   out of hospital Nadroparinstandard prophylaxisnegative
Kakkar and Murray, 1985   nadroparinunfractionated heparingeneral surgerysuggesting-17%
EFS, 1988   nadroparinunfractionated heparinabdominal surgerysuggesting-11%
Dahan, 1989   nadroparinunfractionated heparinthoracic surgerynegative
Barbui, 1990   nadroparinunfractionated heparingeneral surgery -
Eurin, 1994   nadroparinunfractionated heparinabdominal surgery -
phenindione  
Eskeland, 1966   Phenindioneno treatment -
Hamilton, 1970     Phenindioneno treatment -
reviparin  
Wirth, 2001     reviparincontrolLow risk of bias negative
Lassen, 2002     reviparinplaceboLow risk of bias suggesting
Kakkar, 1993   reviparinunfractionated heparingeneral surgery -
rivaroxaban  
MARINER, 2018        NCTrivaroxabanplacebomedical patientsLow risk of bias suggesting 88%-20%
RECORD 1, 2008      NCTrivaroxabanenoxaparinhip surgeryLow risk of bias suggesting202%-2%
RECORD 3, 2008    NCTrivaroxabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting19%-100%
ODIXa-HIP 10mg, 2006   rivaroxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
RECORD 2, 2008    NCTrivaroxaban (long duration)enoxaparin (short duration)hip surgeryLow risk of bias suggesting0%-66%
ODIXa-KNEE, 2005   rivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias negative-100%
RECORD 4, 2009    NCTrivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting147%-34%
suloctidil  
Turpie, 1985   SuloctidilplaceboLow risk of bias -
ticlopidine  
McKenna-II, 1983   TiclopidineplaceboExploratory negative
Lyon-II   TiclopidineplaceboExploratory negative
Gardecki   TiclopidineplaceboExploratory negative
McKenna-II , 1983   ticlopidineplaceboLow risk of bias negative
Lasierra, 1982   ticlopidineplaceboLow risk of bias -
Walker, 1974   ticlopidineplaceboLow risk of bias -
tinzaparin  
Jorgensen, 2002     tinzaparincontrolRisk of bias negative
Lassen, 1991   tinzaparinplacebohip surgeryLow risk of bias suggesting13%
Bergqvist [42]   tinzaparinplacebonegative∞%-100%
Leizorovicz, 1991   tinzaparinunfractionated heparinabdominal surgery -
UFH  
Blech, 1981   UFHcontrolmedical patientssuggesting
Cade   UFHcontrolmedical patients -
Gardlund, 1996   UFHcontrolmedical patientssuggesting
Handley (low dose), 1972   UFHcontrolRisk of bias negative
Handley, 1972   UFHcontrolRisk of bias negative0%
Gallus, 1973   UFHcontrolRisk of bias negative
Emerson, 1973   UFHcontrolRisk of bias suggesting-100%
Zawilska, 1989   UFHcontrolRisk of bias suggesting-12%
Warlow, 1973     UFHcontrolLow risk of bias suggesting20%
Morris, 1974     UFHno treatmentsuggesting
Welin-Berger, 1982   UFHno treatmentnegative
Bergqvist , 1979   UFHno treatmentsuggesting
VTCSG, 1975   UFHno treatmentnegative
Mannucci , 1976   UFHno treatmentsuggesting
Dechavanne, 1974   UFHno treatmentsuggesting
Dechavanne, 1975   UFHno treatmentsuggesting
Bergqvist, 1979   UFHno treatmentsuggesting
Galasko , 1976   UFHno treatmentsuggesting
Gallus , 1973   UFHno treatmentsuggesting
Morris , 1977   UFHno treatmentnegative
Kakkar (IMT)     UFHno treatment -
Gruber     UFHno treatment -
Gordon-Smith, 1972   UFHno treatment -
Nicolaides, 1972     UFHno treatment -
Multiunit, 1974   UFHno treatment -
Abernethy, 1974   UFHno treatment -
Clarke-Pearson, 1983   UFHno treatment -
Plante, 1979     UFHno treatment -
Abraham-Inpijn, 1979   UFHno treatment -
Spebar, 1981   UFHno treatment -
Sagar, 1974     UFHno treatment -
Koppenhagen, 1982   UFHno treatment -
Bergqvist, 1980   UFHno treatment -
Gallus, 1973   UFHno treatment -
Gallus, 1976   UFHno treatment -
Groote Schuur, 1979   UFHno treatment -
Kraytman, 1976   UFHno treatment -
Kraytman, 1977   UFHno treatment -
Kettunen, 1974   UFHno treatment -
Caloghera, 1984   UFHno treatment -
Marchelli, 1983   UFHno treatment -
Ziemski, 1979   UFHno treatment -
Coe, 1978   UFHno treatment -
Sebeseri, 1975   UFHno treatment -
Allen, 1978   UFHno treatment -
Cerrato, 1978   UFHno treatmentsuggesting
Williams , 1978   UFHplacebonegative
Abraham-Inpijn , 1975   UFHplacebonegative
Lowe , 1981     UFHplacebosuggesting
Hampson, 1974     UFHplacebonegative
Moskovitz, 1978   UFHplacebosuggesting
Lahnborg, 1980   UFHplacebosuggesting
Xabregas , 1977   UFHplacebonegative
Moskovitz, 1978   UFHplacebonegative
Svend-Hansen, 1981   UFHplacebosuggesting
Kakkar, 1972     UFHplacebo -
Kiil, 1978     UFHplacebo -
Torngren, 1978   UFHplacebo -
Torngren   UFHplacebo -
Lahnborg, 1975   UFHplacebo -
Lahnborg, 1976     UFHplacebo -
Covey, 1975   UFHplacebo -
Belch, 1980   UFHplacebo -
Taberner, 1978   UFHplacebo -
Strand, 1975   UFHplacebo -
Roberts, 1975   UFHplacebo -
Ribaudo, 1975   UFHplacebo -
Wu, 1977   UFHplacebo -
Lawrence, 1977   UFHplacebo -
Muiticentre, 1984   UFHplacebo -
Jourdan, 1984   UFHplacebo -
Torngren, 1978   UFHplacebo -
Kruse-Blinkenberg, 1980   UFHplacebo -
Kraytman, 1977   UFHplacebo -
Marchetti, 1982   UFHplacebo -
Bejjani, 1983   UFHplacebo -
Hedlund, 1979   UFHplacebo -
Kutnowski, 1977   UFHplacebo -
Vandendris, 1980   UFHplacebo -
Pitt, 1980   UFHplaceboRisk of bias negative
Loew, 1977   UFHaspirin -
Vinazzer, 1980   UFHaspirin -
Muiticentre 53,S4, 1984   UFHDHE -
Muiticentre, 1984   UFHDHE -
van Geloven, 1977   UFHoral anticoagulant -
Manganelli, 1998     out of hospital UFHstandard prophylaxisnegative
warfarin  
Pinto, 1970   Warfarinno treatment -
Hume, 1973   Warfarinno treatment -
Morris, 1976     Warfarinno treatment -
Powers, 1989   Warfarinno treatment -
Myrhe, 1969   WarfarinplaceboLow risk of bias -
RD Heparin, 1994   WarfarinArdeparinsuggesting-53%∞%
Heit, 1997   WarfarinArdeparinLow risk of bias suggesting-88%-100%
Powers, 1989   WarfarinAspirin -
Lotke, 1997     WarfarinAspirin -
Francis, 1997     WarfarinDalteparinsuggesting-34%
Hull, 2000     WarfarinDalteparinLow risk of bias suggesting -71%101%
Gerhart, 1991   WarfarinDanaparoid -
van Comp, 1998   WarfarinDanaparoid -
Myrhe, 1969   WarfarinDextranLow risk of bias -
Harris, 1972   WarfarinDextran -
Barber, 1977   WarfarinDextran -
Francis, 1983   WarfarinDextran -
Leclerc, 1996     WarfarinEnoxaparinLow risk of bias suggesting-14%1%
Colwell, 1999     WarfarinEnoxaparinsuggesting-56%13%
Fitzgerald, 2001     WarfarinEnoxaparinsuggesting -56%195%
Paiement, 1987   WarfarinIntermittent pneumatic compression -
Bailey, 1991   WarfarinIntermittent pneumatic compression -
Kaempffe, 1991     WarfarinIntermittent pneumatic compression -
Francis, 1992   WarfarinIntermittent pneumatic compression -
Hull, 1993     WarfarinLogiparinLow risk of bias suggesting-55%-8044%
Hume, 1973   WarfarinSudoxicam -
Hume, 1973   Warfarinunfractionated heparin -
Barber, 1977   Warfarinunfractionated heparin -
ximelagatran  
METHRO I, 2002   ximelagatranDalteparinnegative
METHRO II, 2002     ximelagatranDalteparinLow risk of bias suggesting101%
Phase II (Heit), 2001     ximelagatranEnoxaparinLow risk of bias negative-100%
Platinum (Colwell), 2003   ximelagatranEnoxaparinLow risk of bias negative -12%
METHRO III, 2002         ximelagatranEnoxaparinLow risk of bias negative-14%
EXPRESS, 2003     ximelagatranEnoxaparinLow risk of bias suggesting 189%

venous thrombosis  

apixaban  
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting-51%
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting-75%
Botticelli DVT, 2008      NCTapixaban (without LMWH)LMWH/VKAExploratory -
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-69%-21%
aspirin  
WARFASA, 2012    NCTaspirindiscontinuationLow risk of bias suggesting-4%15%
ASPIRE, 2012     aspirindiscontinuationsuggesting75%-11%
Bemiparin  
Kakkar, 2003     BemiparinwarfarinRisk of bias negative
dabigatran  
RE-MEDY, 2011      NCTdabigatranwarfarinLow risk of bias suggesting-48%-11%
RE-SONATE, 2011    NCTdabigatrandiscontinuationLow risk of bias suggesting∞%-100%
RE-COVER, 2009      NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-17%-1%
dalteparin  
CLOT (Lee), 2003     extended dalteparinstandard treatmentsuggesting57%-4%
Das, 1996     DalteparinwarfarinRisk of bias negative
Lee, 2003       DalteparinwarfarinRisk of bias suggesting
Holmström, 1992   once daily dalteparintwice daily dalteparinnegative
Partsch, 1996     once daily dalteparintwice daily dalteparinnegative153%
Bratt et al , 1985   Dalteparinunfractionated heparinnegative
Holm et al , 1986   Dalteparinunfractionated heparinnegative
Bratt et al, 1990   Dalteparinunfractionated heparinnegative83%
Lindmarker et al , 1993   Dalteparinunfractionated heparinnegative-32%
edoxaban  
Hokusai-VTE Cancer, 2017      NCTedoxabandalteparinpatients with cancerRisk of bias negative 77%12%
enoxaparin  
Veiga, 2000     EnoxaparinacenocoumarolRisk of bias negative
González-Fajardo, 2008     EnoxaparincoumarinRisk of bias -
Cesarone, 2003   extended enoxaparinstandard treatmentnegative-33%
Deitcher, 2006     extended enoxaparinstandard treatmentnegative204%1%
Meyer, 2002     extended enoxaparinstandard treatmentnegative-56%-20%
Pini, 1994   EnoxaparinwarfarinRisk of bias negative
Gonzalez-Fajardo, 1999     EnoxaparinwarfarinRisk of bias suggesting
Meyer, 2002     EnoxaparinwarfarinRisk of bias negative
Deitcher, 2003   EnoxaparinwarfarinRisk of bias negative
Merli, 2001     once daily enoxaparintwice daily enoxaparinLow risk of bias negative65%
Merli (once daily vs UFH), 2001   once daily enoxaparinUFHLow risk of bias negative19%
Simonneau et al , 1993   Enoxaparinunfractionated heparinnegative50%
fondaparinux  
MATISSE, 2004   fondaparinuxenoxaparinLow risk of bias negative9%25%
MATISSE PE, 2003   fondaparinuxheparinRisk of bias negative-15%19%
heparin  
Ott importé, 1998   heparin+warfarinplaceboLow risk of bias negative
Krahenbuhl, 1979   subcutaneous heparinintravenous heparin -
Bentley, 1980     subcutaneous heparinintravenous heparinsuggesting-75%
Andersson, 1982     subcutaneous heparinintravenous heparin -
Hull, 1986   subcutaneous heparinintravenous heparinnegative 2%
Doyle, 1987   subcutaneous heparinintravenous heparinnegative104%
Walker, 1987   subcutaneous heparinintravenous heparinsuggesting0%
Lopaciuk   subcutaneous heparinintravenous heparinnegative92%
Pini, 1990   subcutaneous heparinintravenous heparinnegative-46%
Nielsen importé, 1994     heparin+phenprocoumonphenylbutazone -
idraparinux  
Van Gogh (subgroup), 2011     idraparinuxstandard treatmentpatients with cancerExploratory negative
VanGogh DVT, 2007    NCTidraparinux (without heparin)heparin/VKAExploratory suggesting-29%3%
VanGogh PE, 2007    NCTidraparinux (without heparin)heparin/VKARisk of bias negative -49%79%
logiparin  
Siegbahn, 1989   once daily logiparintwice daily logiparinnegative
nadroparin  
Lopaciuk, 1999     NadroparinacenocoumarolRisk of bias negative
Lopez-Beret, 2001     NadroparinacenocoumarolRisk of bias negative
Lopez Beret, 2001     extended nadroparinstandard treatmentnegative24%
Charbonnier, 1998     once daily nadroparintwice daily nadroparinLow risk of bias negative-27%
Collaborative European Multicentre, 1991   Nadroparinunfractionated heparinnegative89%
Prandoni et al , 1992   Nadroparinunfractionated heparinsuggesting-50%
Lopaciuk et al , 1992   Nadroparinunfractionated heparinnegative-100%
rivaroxaban  
SELECT D, 2018     rivaroxabandalteparinpatients with cancerRisk of bias suggesting 83%
EINSTEIN-extension, 2009    NCTrivaroxabandiscontinuationLow risk of bias suggesting ∞%-51%
EINSTEIN (subgroup), 2014     rivaroxabanenoxaparinpatients with cancersuggesting-58%-7%
Einstein-DVT Dose-Ranging Study, 2008     rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010    NCTrivaroxaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-30%-23%
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
rosuvastatin  
VanGogh extension, 2007      NCTidraparinuxdiscontinuationsuggesting ∞%
tinzaparin  
Romera, 2009     TinzaparinacenocoumarolRisk of bias suggesting
Hull, 2006     extended tinzaparinstandard treatmentnegative0%5%
Hull, 2002   TinzaparinwarfarinRisk of bias negative
Hull et al , 1992   Tinzaparinunfractionated heparinsuggesting-51%
warfarin  
Schulman, 1995     6 months1.5 monthssuggesting388%-25%
Pinede, 2001     3-6 months1.5-3 monthsnegative73%32%
Wells (subgroup), 2005     tinzaparindalteparinnegative-54%16%
PROLONG (Palareti), 2006      NCTwarfarindiscontinuationsuggesting∞%17%
Levine, 1995   warfarindiscontinuationLow risk of bias suggesting∞%-4%
LAFIT (Kearon), 1999       warfarindiscontinuationsuggesting∞%-65%
Agnelli, 2001     warfarindiscontinuationnegative99%-1%
Agnelli, 2003     warfarindiscontinuationnegative193%67%
PREVENT (Ridker), 2003     warfarindiscontinuationsuggesting148%-50%
ELAET (Kearon), 2004     warfarindiscontinuationLow risk of bias negative∞%
DURAC (Schulman), 1997     warfarindiscontinuationsuggesting219%-40%
ximelagatran  
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting20%-14%
Schulman (subgroup), 2003     ximelagatranplacebopatients with cancer -
Fiessinger , 2005   ximelagatranLMWH/VKALow risk of bias -
THRIVE I, 2003   ximelagatran (without LMWH)LMWH/VKA -